Advertisement

New Long-Acting Hemophilia A Drug Approved — Physician’s First Watch

Medical News |
June 9, 2014

New Long-Acting Hemophilia A Drug Approved

By Kristin J. Kelley

Edited by Susan Sadoughi, MD, and Jaye Elizabeth Hefner, MD

The FDA has approved Eloctate, a new prophylactic treatment for children and adults with hemophilia A. The infusion is long-acting and will decrease the number of doses required, with an infusion needed every 3 to 5 days (rather than three times weekly or every other day).

Eloctate consists of the coagulation factor VIII molecule linked to a protein fragment (Fc), which makes the therapy last longer in the patient's blood.

In a clinical trial of some 160 males aged 12 and older with severe hemophilia, Eloctate effectively treated, reduced, and prevented bleeding episodes. Additionally, it was effective in controlling perioperative bleeding.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement